At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the pooled analysis of tandem autologous-autologous vs. autologous-allogeneic transplantation for 1,338 patients with newly diagnosed multiple myeloma from four trials with long-term follow-up was presented. Speaking from the meeting, Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, explains the results, taken from the BMT CTN 0102, NMAM2000, PETHEMA/GEM2000 and Torino consortium trials, and their impact.
